Clinical Trial Update: Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing outpatient immunotherapy with Rituximab plus Aldesleukin versus Rituximab alone in Non-Hodgkin's lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• Rituximab (rituximab)

Snippet

Sponsor: US Oncology Research | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED